SG11201701016WA - Anti-vasa antibodies, and methods of production and use thereof - Google Patents

Anti-vasa antibodies, and methods of production and use thereof

Info

Publication number
SG11201701016WA
SG11201701016WA SG11201701016WA SG11201701016WA SG11201701016WA SG 11201701016W A SG11201701016W A SG 11201701016WA SG 11201701016W A SG11201701016W A SG 11201701016WA SG 11201701016W A SG11201701016W A SG 11201701016WA SG 11201701016W A SG11201701016W A SG 11201701016WA
Authority
SG
Singapore
Prior art keywords
production
methods
vasa antibodies
vasa
antibodies
Prior art date
Application number
SG11201701016WA
Other languages
English (en)
Inventor
David T Weaver
Bo Zhang
Original Assignee
Ovascience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovascience Inc filed Critical Ovascience Inc
Publication of SG11201701016WA publication Critical patent/SG11201701016WA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y306/00Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/04Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; involved in cellular and subcellular movement (3.6.4)
    • C12Y306/04013RNA helicase (3.6.4.13)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51Complete heavy chain or Fd fragment, i.e. VH + CH1
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515Complete light chain, i.e. VL + CL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG11201701016WA 2014-09-16 2015-09-16 Anti-vasa antibodies, and methods of production and use thereof SG11201701016WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462051130P 2014-09-16 2014-09-16
US201462089054P 2014-12-08 2014-12-08
PCT/US2015/050449 WO2016044436A2 (en) 2014-09-16 2015-09-16 Anti-vasa antibodies, and methods of production and use thereof

Publications (1)

Publication Number Publication Date
SG11201701016WA true SG11201701016WA (en) 2017-03-30

Family

ID=55454121

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201701016WA SG11201701016WA (en) 2014-09-16 2015-09-16 Anti-vasa antibodies, and methods of production and use thereof

Country Status (26)

Country Link
US (4) US9403913B2 (https=)
EP (1) EP3194448A4 (https=)
JP (2) JP2017532953A (https=)
KR (1) KR20170056521A (https=)
CN (1) CN106573985A (https=)
AP (1) AP2017009758A0 (https=)
AU (1) AU2015317813B2 (https=)
BR (1) BR112017003263A2 (https=)
CA (1) CA2959179A1 (https=)
CL (1) CL2017000402A1 (https=)
CO (1) CO2017001724A2 (https=)
CR (1) CR20170067A (https=)
DO (1) DOP2017000050A (https=)
EA (1) EA201790236A1 (https=)
EC (1) ECSP17011262A (https=)
GT (1) GT201700036A (https=)
IL (1) IL250451A0 (https=)
MX (1) MX358243B (https=)
NI (1) NI201700022A (https=)
PE (1) PE20170667A1 (https=)
PH (1) PH12017500309A1 (https=)
SG (1) SG11201701016WA (https=)
SV (1) SV2017005393A (https=)
TN (1) TN2017000066A1 (https=)
TW (1) TW201619194A (https=)
WO (1) WO2016044436A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2494108C2 (ru) 2006-04-07 2013-09-27 Аерпио Терапетикс, Инк. Антитела, которые связывают человеческий белок бета-тирозин фосфатазу (нртрвета), и их использование
WO2013056240A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
BR112017003263A2 (pt) * 2014-09-16 2017-11-28 Ovascience Inc anticorpos anti-vasa, e métodos de produção e utilização dos mesmos
BR112019001206A2 (pt) 2016-07-20 2019-06-25 Aerpio Therapeutics Inc anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss)
WO2020068653A1 (en) 2018-09-24 2020-04-02 Aerpio Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF
WO2020102565A2 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Systems and methods for nondestructive testing of gametes
KR102880907B1 (ko) 2019-11-11 2025-11-04 벤더르빌트 유니버시티 한타바이러스에 대한 인간 모노클로날 항체 및 이의 사용 방법
CN120405134A (zh) * 2024-01-30 2025-08-01 抟相医药(杭州)有限公司 基于凝聚体荧光漂白恢复技术(Drop-FRAP)的生物大分子相互作用调节剂筛选平台

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6094696A (en) * 1995-06-05 1996-12-24 Bionebraska, Inc. Lead binding polypeptides and nucleotides coding therefor
US6875854B1 (en) * 1999-11-18 2005-04-05 The Brigham And Women's Hospital, Inc. Compositions and methods for the improved diagnosis and treatment of germ cell tumors
EP1233978A4 (en) 1999-11-18 2003-07-23 Brigham & Womens Hospital COMPOSITIONS AND METHODS FOR IMPROVED DIAGNOSIS AND TREATMENT OF GERM CELL TUMORS
EP1765983A4 (en) 2004-05-17 2008-10-22 Gen Hospital Corp METHOD AND COMPOSITIONS FOR THE PRODUCTION OF STEM CELLS FROM BUTCHMARK DERIVED GLAND STEM CELLS
US7955846B2 (en) 2004-05-17 2011-06-07 The General Hospital Corporation Compositions comprising female germline stem cells and methods of use thereof
SI1674111T1 (sl) * 2004-07-09 2011-02-28 Chugai Pharmaceutical Co Ltd Protitelo proti glipikanu 3
JPWO2006067847A1 (ja) * 2004-12-22 2008-06-12 中外製薬株式会社 フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法
KR20110055687A (ko) * 2008-09-25 2011-05-25 고쿠리츠 다이가쿠 호우징 도쿄 가이요우 다이가쿠 항참치 Vasa 항체
RU2011131071A (ru) * 2008-12-26 2013-02-10 Дзе Юниверсити Оф Токио Диагностика и лечение рака с помощью антитела против lgr7
WO2011016238A1 (en) * 2009-08-06 2011-02-10 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
CN106350479A (zh) 2011-04-14 2017-01-25 通用医疗公司 用于自体种系线粒体能量转移的组合物和方法
EA201490050A1 (ru) * 2011-06-29 2014-07-30 Зе Дженерэл Хоспитэл Корпорейшн Композиции и способы повышения биоэнергетического состояния женских зародышевых клеток
JP2016503817A (ja) * 2012-12-31 2016-02-08 ディヴェロップメント センター フォー バイオテクノロジー アンチグラニュリシン抗体及びその使用方法
BR112017003263A2 (pt) * 2014-09-16 2017-11-28 Ovascience Inc anticorpos anti-vasa, e métodos de produção e utilização dos mesmos
WO2016115077A1 (en) * 2015-01-13 2016-07-21 President And Fellows Of Harvard College Purification of germ stem cells by targeting mrp9

Also Published As

Publication number Publication date
TW201619194A (zh) 2016-06-01
PE20170667A1 (es) 2017-06-06
US20160311929A1 (en) 2016-10-27
GT201700036A (es) 2018-12-19
AU2015317813B2 (en) 2018-04-05
US20170107299A1 (en) 2017-04-20
CR20170067A (es) 2017-05-10
US20180155445A1 (en) 2018-06-07
BR112017003263A2 (pt) 2017-11-28
JP2017532953A (ja) 2017-11-09
WO2016044436A3 (en) 2016-06-09
AP2017009758A0 (en) 2017-02-28
AU2015317813A1 (en) 2017-03-02
CN106573985A (zh) 2017-04-19
CO2017001724A2 (es) 2017-07-19
ECSP17011262A (es) 2017-05-31
US9403913B2 (en) 2016-08-02
PH12017500309A1 (en) 2017-07-10
CL2017000402A1 (es) 2017-11-03
NI201700022A (es) 2017-05-04
JP2018148915A (ja) 2018-09-27
SV2017005393A (es) 2017-06-07
KR20170056521A (ko) 2017-05-23
IL250451A0 (en) 2017-03-30
MX2017002390A (es) 2017-07-28
US9567404B2 (en) 2017-02-14
TN2017000066A1 (en) 2018-07-04
DOP2017000050A (es) 2018-04-15
EP3194448A4 (en) 2018-03-14
WO2016044436A2 (en) 2016-03-24
EP3194448A2 (en) 2017-07-26
US20160075797A1 (en) 2016-03-17
EA201790236A1 (ru) 2017-11-30
CA2959179A1 (en) 2016-03-24
MX358243B (es) 2018-08-10

Similar Documents

Publication Publication Date Title
IL320713A (en) Antibodies, uses and methods
IL279606A (en) Anti-TREM2 antibodies and methods of using them
IL251868A0 (en) Anti-tim3 antibodies and methods of use
ZA201703167B (en) Anti-cd79b antibodies and methods of use
ZA201800315B (en) Anti-jagged1 antibodies and methods of use
EP3116911B8 (en) Anti-mcam antibodies and associated methods of use
IL248399A0 (en) New anti-43rnf antibodies and methods of use
IL259681A (en) New antibodies against claudin and methods of using them
ZA201701674B (en) Novel anti-mfi2 antibodies and methods of use
GB201403875D0 (en) Novel antibodies and uses thereof
GB201413913D0 (en) Novel antibodies and uses thereof
IL247754A0 (en) Antibodies against mcam and related methods of use
IL251165A0 (en) Anti-il-1beta antibodies and methods of their use
AP2016009400A0 (en) Backfill, methods of making, and use thereof
IL251286A0 (en) Anti-pdgf-b antibodies and methods of use
IL250451A0 (en) Anti-vasa antibodies, and methods for their preparation and use